Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1341-1360 of 1,694 trials

Prucalopride for Refractory Gastro-Esophageal Reflux Disease

We are testing a new medication for patients with GERD who still have symptoms despite taking standard treatments. The goal is to see if this drug can improve their reflux symptoms.

Gastro-esophageal Reflux Disease (GERD)≤3 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

HER2 Positive Esophageal Cancer: HERES Trial

We are studying whether adding trastuzumab to standard chemotherapy and immunotherapy helps patients with HER2 positive esophageal squamous cell carcinoma live longer without disease progression.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Type 3 Spinal Muscular Atrophy: NMD670 Study

We are testing the safety and effectiveness of NMD670 in adults with Type 3 spinal muscular atrophy. The study aims to see if it improves muscle strength and function compared to a placebo.

Spinal Muscular Atrophy Type III3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Non-Small Cell Lung Cancer: Chemotherapy Plus Osimertinib Study

We are evaluating if adding osimertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have progressed after initial osimertinib treatment. This study compares the new treatment approach to chemotherapy with a placebo.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOncology

Knee Osteoarthritis: Bovine vs. Marine Chondroitin Sulfate

We are comparing two types of chondroitin sulfate tablets to see if they help reduce pain and improve function in people with knee osteoarthritis. This study will also look at how these treatments affect quality of life and safety.

Knee Osteoarthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyRheumatology

Chronic Urticaria: Testing Remibrutinib

We are exploring whether remibrutinib can help adults with Chronic Urticaria manage their symptoms better than a placebo. The study also looks at the safety of this new treatment and its effects on quality of life.

Chronic Urticaria≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Alzheimer’s Disease: KarXT for Psychosis

We are testing a new treatment called KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to see if it can reduce symptoms like hallucinations and delusions compared to a placebo.

Psychosis Associated with Alzheimer's Disease3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Genital Herpes: IM-250 Treatment Study

We are investigating a new medication, IM-250, for people with recurrent genital herpes to see if it can help reduce outbreaks. The study will also look at the safety of this treatment when given weekly.

Genital Herpes≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementDermatologyInfectious Diseases

Heart Health: Treatment for Frequent PVCs

We are studying whether treating asymptomatic patients with frequent PVCs can prevent future heart function problems. This trial compares treatment options to simple monitoring to see which is more effective.

Premature Ventricular Contractions (PVCs)>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Post-COVID-19 Condition: Plitidepsin Study

We are investigating whether plitidepsin can improve health outcomes for adults with post-COVID-19 Condition. The study will compare its effects to a placebo on symptoms and overall well-being.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinologyGastroenterologyHematologyInfectious DiseasesInternal MedicineNeurologyPsychiatryPulmonologyRheumatology

Immune Thrombocytopenia: Dexamethasone vs. IVIg

We are studying whether oral dexamethasone is as effective as intravenous immunoglobulin combined with prednisone for adults with immune thrombocytopenia experiencing bleeding. This research may help identify a more convenient treatment option.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Sepsis Treatment: Hydrocortisone and Fludrocortisone Study

We are investigating whether a combination of hydrocortisone and fludrocortisone can improve outcomes for adults with sepsis in the ICU. This study aims to see if it helps reduce death or ongoing organ issues compared to a placebo.

Sepsis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Bariatric Surgery: Metformin for Diabetes Management

We are studying whether adding metformin to standard care helps people who had bariatric surgery stay diabetes-free longer. This trial focuses on former type 2 diabetes patients and their overall health and quality of life.

Type 2 Diabetes>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Glycerol Phenylbutyrate for Pyruvate Dehydrogenase Deficiency

We are studying whether Glycerol Phenylbutyrate can help reduce fatigue and improve quality of life for patients with Pyruvate Dehydrogenase Deficiency. The trial will also assess its safety and effects on neurodevelopmental symptoms.

Pyruvate Dehydrogenase Deficiency1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGastroenterologyNeurology

Seizures in Developmental and Epileptic Encephalopathies: LP352 Study

We are investigating whether LP352 can help reduce seizures in children and adults with developmental and epileptic encephalopathies. This study compares the medication to a placebo to assess its effectiveness and safety.

Developmental and Epileptic EncephalopathiesConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Multiple Myeloma: Elranatamab and Lenalidomide Study

We are testing a new combination treatment for newly diagnosed multiple myeloma to see if it works better than standard therapies. The study aims to evaluate its effectiveness and safety during different treatment phases.

Multiple Myeloma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Kidney Cancer: New Combination Therapies

We are studying new treatment combinations for people with recurrent kidney cancer after anti-PD-(L)1 therapy. The goal is to evaluate their safety and effectiveness in improving patient responses.

Clear Cell Renal Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Obstructive Colon Cancer: Neoadjuvant Chemotherapy Study

We are studying whether two chemotherapy regimens can improve treatment outcomes for patients with obstructive colon cancer after colostomy. The goal is to see if starting chemotherapy before surgery leads to better recovery and survival rates.

Colon Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Chronic Hypertension in Pregnancy: Aspirin Study

We are investigating whether low-dose aspirin can help prevent serious complications in pregnant women with chronic hypertension. This includes risks like preeclampsia and preterm delivery.

Pregnancy-Related Hypertension and Pre-Eclampsia6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Friedreich Ataxia: Vatiquinone Safety Study

We are studying the long-term safety of vatiquinone in patients with Friedreich Ataxia who have previously used this medication. We aim to see how it affects their symptoms over time.

Friedreich's Ataxia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurology